Zurich-based healthtech startup Aeon has raised €8.2 million in seed funding to advance its AI-driven platform for preventive diagnostics.
The round was led by London-based VC firm Concentric, with participation from Calm/Storm Ventures, GoHub Ventures, Kadmos Capital, EWOR, and angel investor Daniel Gutenberg.
Funding to fuel expansion and partnerships
Aeon plans to use the capital to expand its presence across Switzerland, Germany, and the UK. The company also aims to forge partnerships with insurers and employers to make preventive health services more accessible and affordable. Part of the funds will go toward enhancing Aeon’s AI platform for faster, more accurate disease detection.
Advertisement
AI-driven diagnostics with zero false positives
Founded in 2023 by Tim Seithe (CEO) and Samuel Frey (CPO), the HealthTech combines whole-body MRI, blood biomarker analysis, and genetic testing to screen for over 500 diseases. The company claims a 0% false positive rate in clinical follow-ups and has already flagged early signs of conditions like cancer and Alzheimer’s in asymptomatic patients.
Insurance-backed preventive care
Aeon’s check-ups are reimbursed by major insurers in Switzerland, such as KPT, with customers eligible to receive up to 80% of the cost back. This positions the startup as the first provider of full-body preventive diagnostics covered by insurance in the region.
“We’re redefining preventive care by focusing on accuracy, accessibility, and personalization,” said CEO Tim Seithe. “Our platform shifts healthcare from reactive treatment to proactive risk management.”
